title: Mortality among British Columbians testing for hepatitis C antibody.
abstract: BACKGROUND
  Hepatitis C virus (HCV) infection is a major preventable and treatable cause of morbidity and mortality. The ability to link population based centralized laboratory HCV testing data with administrative databases provided a unique opportunity to compare mortality between HCV seronegative and seropositive individuals. Through the use of laboratory testing patterns and results, the objective of this study was to differentiate the viral effects of mortality due to HCV infection from risk behaviours/activities that are associated with acquisition of HCV infection.
  
  
  METHODS
  Serological testing data from the British Columbia (BC) Centre for Disease Control Public Health Microbiology and Reference Laboratory from 1992-2004 were linked to the BC Vital Statistics Agency death registry. Four groups of HCV testers were defined by their HCV antibody (anti-HCV) testing patterns: single non-reactive (SNR); serial multiple tested non-reactive (MNR); reactive at initial testing (REAC); and seroconverter (SERO) (previously seronegative followed by reactive, a marker for incident infection). Standardized mortality ratios (SMRs) were calculated to compare the relative risk of all cause and disease specific mortality to that of the BC population for each serological group. Time dependent Cox proportional hazard regression was used to compare hazard ratios (HRs) among HCV serological groups.
  
  
  RESULTS
  All anti-HCV testers had higher SMRs than the BC population. Referent to the SNR group, the REAC group had higher risks for liver (HR: 9.62; 95% CI=8.55-10.87) and drug related mortality (HR: 13.70; 95% CI=11.76-16.13). Compared to the REAC group, the SERO group had a lower risk for liver (HR: 0.53; 95% CI=0.24-0.99), but a higher risk for drug related mortality (HR: 1.54; 95% CI=1.12-2.05).
  
  
  CONCLUSIONS
  These findings confirm that individuals who test anti-HCV positive have increased mortality related to progressive liver disease, and that a substantial proportion of the mortality is attributable to drug use and risk behaviours/activities associated with HCV acquisition. Mortality reduction in HCV infected individuals will require comprehensive prevention programming to reduce the harms due to behaviours/activities which relate to HCV acquisition, as well as HCV treatment to prevent progression of chronic liver disease.
authors.affiliation: BC Centre for Disease Control, 655 West 12th Avenue, Vancouver, BC V5Z 4R4, Canada.
authors.forename: Amanda
authors.initials: A
authors.lastname: Yu
authors.forename: John J
authors.initials: JJ
authors.lastname: Spinelli
authors.forename: Darrel A
authors.initials: DA
authors.lastname: Cook
authors.forename: Jane A
authors.initials: JA
authors.lastname: Buxton
authors.forename: Mel
authors.initials: M
authors.lastname: Krajden
mesh_terms: D000328:Adult; D001955:British Columbia / Q000453:epidemiology; D002423:Cause of Death / Q000639:trends; D016208:Databases, Factual; D005260:Female; D006526:Hepatitis C / Q000401:mortality* / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D008107:Liver Diseases / Q000401:mortality* / Q000821:virology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018570:Risk Assessment; D012309:Risk-Taking; D019966:Substance-Related Disorders / Q000401:mortality* / Q000821:virology
chemical_list: D018937:Hepatitis C Antibodies
references.citation: J Viral Hepat. 2008 Jul;15(7):538-50
references.pmid: 18397223
references.citation: Clin Gastroenterol Hepatol. 2011 Sep;9(9):786-792.e1
references.pmid: 21699803
references.citation: Hepatology. 2011 May;53(5):1742-51
references.pmid: 21374691
references.citation: Hepatology. 2012 Jan;55(1):49-57
references.pmid: 21898506
references.citation: Am J Epidemiol. 2011 Oct 15;174(8):969-76
references.pmid: 21920949
references.citation: Clin Infect Dis. 2011 Jul 15;53(2):150-7
references.pmid: 21665867
references.citation: BMC Public Health. 2009 Jul 29;9:270
references.pmid: 19640297
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S35-46
references.pmid: 12407575
references.citation: Hepatology. 2008 Aug;48(2):418-31
references.pmid: 18563841
references.citation: Liver Int. 2011 Jan;31 Suppl 1:18-22
references.pmid: 21205133
references.citation: Am J Epidemiol. 2010 Mar 1;171(5):602-8
references.pmid: 20106936
references.citation: Am J Manag Care. 2004 Mar;10(2 Suppl):S21-9
references.pmid: 15084064
references.citation: Arch Intern Med. 2011 Feb 14;171(3):242-8
references.pmid: 21325115
references.citation: J Hepatol. 2010 Jul;53(1):36-42
references.pmid: 20400197
references.citation: IARC Sci Publ. 1987;(82):1-406
references.pmid: 3329634
references.citation: Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1
references.pmid: 21397729
references.citation: Lancet. 2006 Sep 9;368(9539):938-45
references.pmid: 16962883
references.citation: Can J Gastroenterol. 2010 Dec;24(12):717-26
references.pmid: 21165379
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S21-9
references.pmid: 12407573
references.citation: Liver Transpl. 2003 Nov;9(11):S10-3
references.pmid: 14586889
references.citation: Clin Transplant. 2006 Jan-Feb;20(1):1-9
references.pmid: 16556146
references.citation: Hepatology. 2006 Sep;44(3):521-6
references.pmid: 16941687
references.citation: J Viral Hepat. 2011 Apr;18(4):237-44
references.pmid: 20337923
references.citation: Stat Methods Med Res. 2009 Jun;18(3):271-83
references.pmid: 19036907
references.citation: Harm Reduct J. 2009 Mar 05;6:5
references.pmid: 19265531
references.citation: Can J Gastroenterol. 2000 Jul-Aug;14(7):575-80
references.pmid: 10978943
references.citation: J Viral Hepat. 2001 Mar;8(2):87-95
references.pmid: 11264728
references.citation: BMC Public Health. 2010 Apr 29;10:225
references.pmid: 20429917
references.citation: BMJ. 2002 Feb 23;324(7335):450-3
references.pmid: 11859045
references.citation: Annu Rev Public Health. 1999;20:145-57
references.pmid: 10352854